Destination Wealth Management
BIB icon

Destination Wealth Management’s ProShares Ultra NASDAQ Biotechnology BIB Stock Holding History

Destination Wealth Management’s Portfolio BIB Stock Details BIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-179
Closed -$5K – 520
2018
Q1 		$5K Buy
+179
New +$10.7K ﹤0.01% 439

Other funds holding BIB

OPPM
Opus Point Partners Management New York $55.3M AUM 7.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
CIC
Chase Investment Counsel Charlottesville, Virginia $474M AUM 95.11% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
TFA
Toth Financial Advisory Leesburg, Virginia $1B AUM 19.18% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
BA
BKS Advisors Southfield, Michigan $249M AUM 14.37% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
SAM
Stansberry Asset Management Westlake, Texas $1.09B AUM 23.97% 1-Year Est. Return
BRC
Bell Rock Capital Rehoboth Beach, Delaware $81M AUM 9.85% 1-Year Est. Return

Destination Wealth Management's BIB Position: Q2 2018 in Review

Destination Wealth Management sold out of ProShares Ultra NASDAQ Biotechnology (BIB) in Q2 2018, closing a stake of 179 shares — an estimated $5K sold.

Destination Wealth Management first reported a position in BIB in Q1 2018 and held it in 1 quarter. The position peaked at $5K in Q1 2018. 38 funds tracked by Wall St. Rank hold BIB as of Q2 2018.

  • Destination Wealth Management reported no remaining ProShares Ultra NASDAQ Biotechnology position as of Q2 2018 after selling out during the quarter.
  • Destination Wealth Management sold 179 ProShares Ultra NASDAQ Biotechnology shares in Q2 2018, an estimated $5K.
  • Destination Wealth Management first reported a position in ProShares Ultra NASDAQ Biotechnology in Q1 2018 and held it in 1 quarter.
  • Destination Wealth Management's ProShares Ultra NASDAQ Biotechnology position peaked at $5K in Q1 2018.
  • 38 funds tracked by Wall St. Rank held ProShares Ultra NASDAQ Biotechnology as of Q2 2018.

Based on Destination Wealth Management's 13F filing for Q2 2018, filed 31 Jul 2018.